R&D channel feed – Endpoints News

R&D channel feed

Why non-opioid pain drugs keep failing — and what's next for the field

3 years ago

UniQure halts high-dose treatments of Huntington's drug after 3 patients hospitalized — shares tank

3 years ago

Reata continues to hit FDA roadblocks with its Friedreich’s ataxia candidate, noting regulator 'concerns'

3 years ago

Karuna's schizophrenia drug passes a closely-watched PhIII test, will head to FDA in mid-2023

3 years ago

AstraZeneca pushes forward with Tagrisso combos, touting PhII data with Hutchmed drug

3 years ago

In a fresh disappointment, Amgen spotlights a major safety issue with KRAS combo

3 years ago

US declares monkeypox a national health emergency, as new drugmakers consider entering vaccine race

3 years ago

Al Sandrock prunes his post-Biogen voyage with similar focus on ALS

3 years ago

While Praxis moves forward, Neurocrine drops its essential tremor drug

3 years ago

Akebia's anemia drug flunked Covid study — but count the bruised biotech 'extremely encouraged'

3 years ago

Amgen sweeps last BCMA BiTE standing out of pipeline

3 years ago

Novo Nordisk to make all doses of its weight loss drug available in the US by end of the year

3 years ago

AstraZeneca partner Pieris ends work on HER2 drug tested in combo with Eli Lilly, Seagen cancer meds

3 years ago

Weeks after starting, Amgen flashes yellow light on PhIII of $400M eczema bet

3 years ago

Amgen chief Bradway nabs a rare disease player in $4B buyout as the M&A tempo accelerates

3 years ago

Pfizer terminates PhIII study of rare cardiovascular drug picked up in $11.4B Array acquisition

3 years ago

After getting hopes up, expectations on Gilead, Arcus' CD73 'dimmed' on new update

3 years ago

Travere fails to convince regulators to consider accelerated approval for a rare kidney disease — again

3 years ago

CDC, NIH, FDA leaders call for US-based clinical trial of smallpox drug in treating monkeypox

3 years ago

Horizon lowers expectations for Tepezza and adjusts its strategy for the year ahead

3 years ago

After a bust with knee pain drug and 3 Covid-19 flops, Ampio lays off staff; Antibody startup nabs second deal in two weeks

3 years ago

Despite $5B sales for Keytruda, Merck hits two PhIII snags as it continues to build its multibillion-dollar drug

3 years ago

Incyte axes JAK1 inhibitor from pipeline two years after a PhIII flop crushed hopes

3 years ago

PhIII fail in overall survival measure clouds Ipsen's expansion plans for cancer drug Onivyde

3 years ago

First page Previous page 124 125 126127128 129 130 Next page Last page